GJMic.070106

Review

Prospective Interception at the Low Fungal Burden Stage: A Comparative Study of Diagnostic-Driven versus Empiric Antifungal Strategies in Febrile Patients with Hematological Malignancies

Shan Liu1,#, Xiaoxuan Liu1,#, Mingxin He1,#, Danyu Wang1, Mengdi Jin1, Jianhong Xiao1, Liqiong Liu1, Zhi Guo1,*

1Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China.

#,Authors contributed equally
*, Correspondence
Prof. Zhi Guo, Ph.D, MD., Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, Guangdong Province, China. Email: guozhi77@126.com. 
Received: June 30, 2026; Accepted: July 5, 2026; Published online: November 12, 2026.
Cite this paper: Shan Liu, Xiaoxuan Liu, Mingxin He, Danyu Wang, Mengdi Jin, Jianhong Xiao, Liqiong Liu, Zhi Guo. Prospective Interception at the Low Fungal Burden Stage: A Comparative Study of Diagnostic-Driven versus Empiric Antifungal Strategies in Febrile Patients with Hematological Malignancies. Global Journal of Microbiology, 2026;7(1):38-56. http://naturescholars.com/gjmic.070106. https://doi.org/10.46633/gjmic.070106.
Copyright © 2026 by Scholars Publishing, LLC

Abstract

Objective: Empiric therapy (ET) for invasive fungal disease (IFD) in hematological malignancies often causes overtreatment. Diagnostic-driven therapy (DDT) offers a precision paradigm, but real-world host dynamics at clinical decision thresholds remain unclear. This study compared the clinical efficacy, safety, and biological profiles of ET versus DDT. Methods: We retrospectively analyzed 72 patients with hematological malignancies receiving systemic antifungals (ET, n=31; DDT, n=41) between 2023 and 2025. Inflammatory markers and fungal cell wall antigens (G/GM assays) were evaluated at treatment initiation. Multivariable logistic regression identified independent risk factors for breakthrough IFD and drug toxicities. One-year overall survival (OS) was analyzed using Kaplan-Meier methods. Results: Baseline characteristics were well-balanced (P>0.05). At treatment initiation, the DDT group had higher inflammatory loads (median CRP: 26.50 vs. 8.19 mg/L, P=0.0046) and active fever (46.3% vs. 9.7%, P<0.001), whereas the ET group had higher G/GM positivity (45.8% vs. 20.5%, P=0.0335). Multivariable regression showed DDT did not increase risks for breakthrough IFD (OR=1.35, 95% CI: 0.33–5.42, P=0.6754), hepatotoxicity, or nephrotoxicity. Kaplan-Meier analysis demonstrated equivalent 1-year OS (P=0.50). Baseline CRP predicted 1-year mortality better than PCT (AUC: 0.670 vs. 0.593). Conclusions: The DDT strategy provides comparable 1-year survival to ET without increasing breakthrough IFD or toxicities. Baseline CRP serves as a valuable prognostic biomarker for 1-year mortality in this population.

Keywords

Hematological malignancies; Diagnostic-driven therapy; Empiric antifungal therapy; Invasive fungal disease; C-reactive protein.